David A. Orlando, Ph.D.

2009 Computational Biology and Bioinformatics Duke University, Durham, NC 
Bioinformatics, Genetics
"David Orlando"


Sign in to add mentor
Steven B. Haase grad student Duke University/ Department of Biology (Physics Tree)
Philip N. Benfey grad student 2009 (Plant Biology Tree)
 (Regulation of global transcription dynamics during cell division and root development)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Campione SA, Kelliher CM, Orlando DA, et al. (2023) Alignment of Synchronized Time-Series Data Using the Characterizing Loss of Cell Cycle Synchrony Model for Cross-Experiment Comparisons. Journal of Visualized Experiments : Jove
Hu S, Marineau JJ, Rajagopal N, et al. (2019) Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research
Hu S, Marineau J, Hamman K, et al. (2019) Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo Cancer Research. 79: 4421-4421
Ke N, Johannessen L, Rajagopal N, et al. (2019) Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models Cancer Research. 79: 4409-4409
Guenther M, Lambert A, Chen M, et al. (2018) Abstract P2-04-03: Epigenomic analysis of cancer stem cell (CSC)-enriched triple-negative breast cancer (TNBC) populations reveals gene regulatory circuitry and novel tumor cell vulnerabilities Cancer Research. 78
Rajagopal N, Hodgson G, Hu S, et al. (2018) Abstract P1-09-08:BCL2L1(BCL-XL) expression and MYC super-enhancer positivity predict sensitivity to the covalent CDK7 inhibitor SY-1365 in triple negative breast cancer (TNBC) cell lines Cancer Research. 78
Konstantinopoulos PA, Hodgson G, Rajagopal N, et al. (2018) Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo Cancer Research. 78: 1525-1525
McKeown MR, Corces MR, Eaton ML, et al. (2017) Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. Cancer Discovery
Hu S, Ke N, Ren Y, et al. (2017) Abstract 1151: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors Cancer Research. 77: 1151-1151
Bradley M, Marineau J, Choi Y, et al. (2017) Abstract 1143: Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer Cancer Research. 77: 1143-1143
See more...